Comparative analysis of type 2 diabetes-associated gut microbiota between Han and Mongolian people

Li, Shuchun; Xiao, Yao; Wu, Ritu; Xie, Dan; Zhao, Hongxin; Shen, Gangyi; Enqi, Wu

doi:10.1007/s12275-021-0454-8

Cited by 13 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in the T2D group, the genus was the highest than other two groups, that was a different result contrasting that of another research in ethnic Han population, which the genus’ quantity in T2D was lower than that in control [ 29 ]. Meanwhile, similar results as the study were not discovered in other researches [ 4 , 30 , 31 ], that could be contributed to the difference of testing method. We also found a difference in species level, Firmicutes bacterium CAG:341.…”

Section: Discussionsupporting

confidence: 52%

Differences in gut microbiota and its metabolic function among different fasting plasma glucose groups in Mongolian population of China

Yanchao

Wang

et al. 2023

BMC Microbiol

View full text Add to dashboard Cite

Background Many studies reported the association between gut microbiota and type 2 diabetes mellitus (T2D), but it is still unclear which bacterial genus plays a key role and how the metabolic function of gut microbiota changes in the occurrence and development of T2D. Besides, there is a high diabetic prevalence in Mongolian population, which may be partly affected by their high calorie diet. This study identified the main bacterial genus influencing T2D in Mongolian population, and analyzed the changes of metabolic function of gut microbiome. The association between dietary factors and the relative abundance of main bacterial genus and its metabolic function was also studied. Methods Dietary surveys and gut microbiota test were performed on 24 Mongolian volunteers that were divided into T2D (6 cases), PRET2D (6 cases) and Control group (12 cases) according to fasting plasma glucose (FPG) values. The relative abundance and metabolic function of gut microbiome from their fecal samples were measured by metagenomic analysis. Statistic method was used to evaluate the association between dietary factors and the relative abundance of the main bacterial genus or its metabolic function. Results This study found that the Clostridium genus may be one of the key bacterial genera affecting the process of T2D. First, the relative abundance of Clostridium genus was significantly different among the three groups. Second, there was a higher relative abundance of metabolic enzymes of gut bacteria in PRET2D and T2D group than that in Control group. Third, a strong correlation between Clostridium genus and many metabolic enzymes was uncovered, many of which may be produced by the Clostridium. Last, carotene intake daily was negatively correlated with the Clostridium but positively correlated with tagaturonate reductase catalyzing interconversions of pentose and glucuronate. Conclusions The gut Clostridium genus may play an important role in the development of T2D and it could be a potential biomarker for T2D in Mongolian population. Meanwhile, the metabolic function of gut bacteria has changed during the early stage of T2D and the changes in carbohydrate, amino acid, lipid or energy metabolism of Clostridium genus may play a critical role. In addition, the carotene intake may affect reproduction and metabolic function of Clostridium genus.

show abstract

Section: Discussionsupporting

confidence: 52%

Differences in gut microbiota and its metabolic function among different fasting plasma glucose groups in Mongolian population of China

Yanchao

Wang

et al. 2023

BMC Microbiol

View full text Add to dashboard Cite

show abstract

“…This suggested that metformin medication could potentially benefit many relevant disorders. Oscillibacter was reported to be enriched in T2D [ 44 ] and also negatively associated with intestinal barrier function [ 45 ]. In addition, one experimental study showed that Oscillibacter was a potentially important gut microbe that mediated a high-fat diet-induced gut dysfunction in mice [ 46 ].…”

Section: Discussionmentioning

confidence: 99%

Bi-Directional Interactions between Glucose-Lowering Medications and Gut Microbiome in Patients with Type 2 Diabetes Mellitus: A Systematic Review

Li,

Shokri,

Rincon

et al. 2023

Genes

View full text Add to dashboard Cite

Background: Although common drugs for treating type 2 diabetes (T2D) are widely used, their therapeutic effects vary greatly. The interaction between the gut microbiome and glucose-lowering drugs is one of the main contributors to the variability in T2D progression and response to therapy. On the one hand, glucose-lowering drugs can alter gut microbiome components. On the other hand, specific gut microbiota can influence glycemic control as the therapeutic effects of these drugs. Therefore, this systematic review assesses the bi-directional relationships between common glucose-lowering drugs and gut microbiome profiles. Methods: A systematic search of Embase, Web of Science, PubMed, and Google Scholar databases was performed. Observational studies and randomised controlled trials (RCTs), published from inception to July 2023, comprising T2D patients and investigating bi-directional interactions between glucose-lowering drugs and gut microbiome, were included. Results: Summarised findings indicated that glucose-lowering drugs could increase metabolic-healthy promoting taxa (e.g., Bifidobacterium) and decrease harmful taxa (e.g., Bacteroides and Intestinibacter). Our findings also showed a significantly different abundance of gut microbiome taxa (e.g., Enterococcus faecium (i.e., E. faecium)) in T2D patients with poor compared to optimal glycemic control. Conclusions: This review provides evidence for glucose-lowering drug and gut microbiome interactions, highlighting the potential of gut microbiome modulators as co-adjuvants for T2D treatment.

show abstract

“…Conversely, the significant increases in the Alistipes and Ruminococcus genera indicate their presence may act to drive the development of T2D. While Alistipes relative abundance is increased in prediabetic and diabetic patients and in hyperglycemic mice, a causal role for increased Alistipes in T2D has not been established [ 50 , 51 , 52 ]. Ruminococcus is also increased in prediabetic and diabetic patients, and although its role in diabetes development is unclear, increases in Ruminococcus are associated with increased intestinal inflammation which could lead to gut barrier dysfunction and further metabolic consequences, potentially initiating disease development [ 53 , 54 , 55 ].…”

Section: Discussionmentioning

confidence: 99%

Longitudinal Characterization of the Gut Microbiota in the Diabetic ZDSD Rat Model and Therapeutic Potential of Oligofructose

et al. 2023

View full text Add to dashboard Cite

The complex development of type 2 diabetes (T2D) creates challenges for studying the progression and treatment of the disease in animal models. A newly developed rat model of diabetes, the Zucker Diabetic Sprague Dawley (ZDSD) rat, closely parallels the progression of T2D in humans. Here, we examine the progression of T2D and associated changes in the gut microbiota in male ZDSD rats and test whether the model can be used to examine the efficacy of potential therapeutics such as prebiotics, specifically oligofructose, that target the gut microbiota. Bodyweight, adiposity, and fed/fasting blood glucose and insulin were recorded over the course of the study. Glucose and insulin tolerance tests were performed, and feces collected at 8, 16, and 24 weeks of age for short-chain fatty acids and microbiota analysis using 16s rRNA gene sequencing. At the end of 24 weeks of age, half of the rats were supplemented with 10% oligofructose and tests were repeated. We observed a transition from healthy/nondiabetic to prediabetic and overtly diabetic states, via worsened insulin and glucose tolerance and significant increases in fed/fasted glucose, followed by a significant decrease in circulating insulin. Acetate and propionate levels were significantly increased in the overt diabetic state compared to healthy and prediabetic. Microbiota analysis demonstrated alterations in the gut microbiota with shifts in alpha and beta diversity as well as alterations in specific bacterial genera in healthy compared to prediabetic and diabetic states. Oligofructose treatment improved glucose tolerance and shifted the cecal microbiota of the ZDSD rats during late-stage diabetes. These findings underscore the translational potential of ZDSD rats as a model of T2D and highlight potential gut bacteria that could impact the development of the disease or serve as a biomarker for T2D. Additionally, oligofructose treatment was able to moderately improve glucose homeostasis.

show abstract

Comparative analysis of type 2 diabetes-associated gut microbiota between Han and Mongolian people

Cited by 13 publications

References 26 publications

Differences in gut microbiota and its metabolic function among different fasting plasma glucose groups in Mongolian population of China

Differences in gut microbiota and its metabolic function among different fasting plasma glucose groups in Mongolian population of China

Bi-Directional Interactions between Glucose-Lowering Medications and Gut Microbiome in Patients with Type 2 Diabetes Mellitus: A Systematic Review

Longitudinal Characterization of the Gut Microbiota in the Diabetic ZDSD Rat Model and Therapeutic Potential of Oligofructose

Contact Info

Product

Resources

About